The agreement lasted twelve days. On August 6, the German Medical Association (KBV) and the statutory health insurance umbrella organization (GKV-Spitzenverband) jointly clarified how new rules for prescribing cannabis medications should be interpreted. On August 18, the KBV revoked this interpretation. After further legal review, it now demands in every case a preliminary trial with a cannabis-containing finished medication, even outside approved indications. The GKV-Spitzenverband does not support this reversal. Two major self-regulatory bodies now stand opposed with conflicting interpretations of the same law.
📑 Inhaltsverzeichnis
We described the joint interpretation in early August under the headline KBV and GKV-Spitzenverband bring clarity. That article reflects the status as of August 6. For new patients, it no longer applies in one crucial aspect.
How the KBV’s interpretation has changed
The GKV Contribution Rate Stabilization Act took effect on July 30, 2026. It removed cannabis flowers from reimbursement by statutory health insurance. Reimbursement for extracts and compounded preparations remains intact, but the legislature added a hurdle. Before the first prescription, there must be a six-month trial with a cannabis-containing finished medication.
This hurdle is precisely where the dispute originates. On August 6, both bodies declared that the trial requirement applies only where an approved finished medication actually exists for the given indication. In the KBV’s view, this limitation no longer stands.
According to the KBV’s renewed legal review, the statutory requirement for a six-month preliminary trial with a cannabis-containing finished medication should be interpreted as follows: in every case, a cannabis-containing finished medication must first be prescribed, even outside its approved indications.
The KBV no longer holds the position it previously shared with the GKV-Spitzenverband. The statutory health insurance umbrella organization has not adopted this reversal. The very joint interpretation meant to establish legal certainty has become a point of contention.
Off-label use before approved therapy
The new interpretation has a medically remarkable consequence. The range of approved cannabis-containing finished medications is small, and their approvals are narrowly defined. Sativex is approved for spasticity in multiple sclerosis; Canemes for nausea and vomiting under chemotherapy; Epidyolex for certain severe forms of epilepsy. A patient with chronic pain falls under none of these indications.
Under the KBV’s new interpretation, she would still receive one of these medications first—off-label, outside its approved use. Off-label use thus becomes a prerequisite for obtaining a medication that is clinically appropriate for her. Physicians face increased liability risks when prescribing outside approved indications. The law was intended to reduce costs, but it now shifts additional responsibility onto medical practices.
For existing patients, both interpretations maintain current care arrangements. Anyone already being treated with dronabinol, extracts, or compounded preparations before June 30, 2026, requires no preliminary trial.
Who bears the risk
The consequences of this interpretive dispute do not fall on the institutions but land at the end of the chain. Physicians must decide which interpretation to follow and bear the consequences if audited. Pharmacies risk chargebacks if the insurance company later reassesses a prescription differently. Patients usually learn about all this only at the pharmacy counter.
Criticism from the industry has been correspondingly sharp. The Federal Association of Pharmaceutical Cannabis Companies calls it a grave failure and demands clarification from the Federal Health Ministry. Felix Maertin, a Karlsruhe pharmacist, has issued a 14-day ultimatum to responsible authorities and submitted a catalog of questions. The Working Group Cannabis as Medicine is preparing to take the matter to Germany’s constitutional court. We described how this legal strategy is structured in our analysis on how the GKV flower ban is being legally challenged.
A repeating pattern
This incident is not an anomaly but a continuation of a pattern. During the legislative process, it was foreseeable that removing flower reimbursement would affect extracts. In July we reported that extract reimbursement was also at risk, and we documented the Bundestag decision establishing priority for finished medications.
The deeper issue lies one level down. A medically consequential decision was formulated in the law so vaguely that two self-regulatory bodies must fill the gap with interpretive guidance. As long as the Federal Health Ministry remains silent, medical practices decide at their own risk. That federal policymakers recognize the need for corrections in cannabis law is evident from the demands Hendrik Streeck articulated before the committee meeting. We detailed how differently parties view cannabis policy in our electoral analysis of the Saxony-Anhalt state election.
Frequently asked questions
As an existing patient, must I now test a finished medication?
No. If you were already receiving dronabinol, an extract, or a compounded preparation before June 30, 2026, you are exempt from the preliminary trial requirement. This applies under both the old and new interpretations. Follow-up prescriptions are possible without intermediate steps.
What changes for new patients?
Under the KBV’s new interpretation, a cannabis-containing finished medication always comes first, regardless of indication. Under the GKV-Spitzenverband’s interpretation, this applies only where an approved medication exists for that indication. Which approach prevails remains unclear until the Federal Health Ministry weighs in.
Which cannabis-containing finished medications are actually available?
The selection is limited. Approved medications include Sativex for spasticity from multiple sclerosis, Canemes for nausea and vomiting from chemotherapy, and Epidyolex for certain severe forms of epilepsy. For the large group of pain patients, none of these medications is approved.
Can the preliminary trial be ended early?
Yes. If the finished medication causes tolerability issues or demonstrably does not work, the treating physician can discontinue the trial before six months and switch to an extract or dronabinol. A second approved medication need not be tested first. The clinical reasoning should be carefully documented.
What can affected people do concretely now?
An early conversation with the prescribing practice about documentation and timing of the first prescription is worthwhile. Those already in treatment should ensure unbroken continuation of prescriptions, as protected status depends on it. If the insurance company denies coverage, filing an appeal is the standard procedure.
Sources: German Medical Association, Practice Information on Cannabis Prescriptions, as of August 18, 2026; Medical Association of Baden-Württemberg, What applies in cannabis care; GKV Contribution Rate Stabilization Act, in effect since July 30, 2026; Krautinvest; Business of Cannabis.
Note: This article reflects the status as of August 2026 and does not constitute medical or legal advice. Questions about which prescriptions are possible in individual cases and who bears costs should be directed to the treating practice and the respective health insurance company. Ongoing therapies should not be changed without professional guidance.
Sollten Ärzte Cannabis-Fertigarzneimittel off-label verordnen müssen?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
